First it was Teladoc merging with Livongo, next Ascensia offering a lifeline for Senseonics and finally Medtronic acquires Companion Medical. Of these three deals only the Medtronic/Companion deal seems to make sense. Teladoc merging with Livongo has a strategic rationale behind it but Teladoc is vastly overpaying for Livongo. Yet the Ascensia lifeline to Senseonics remains a mystery.
Let’s be very clear here there is nothing wrong with Eversense sensor. The system works just fine and yes there is a niche market for an implantable sensor. However Eversense even if it becomes a 180-day sensor will never . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.